Cite
1017P AdvanTIG-105: Phase Ib dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS) with chemotherapy (chemo) in patients (pts) with metastatic squamous (sq) and non-squamous (non-sq) non-small cell lung cancer (NSCLC).
MLA
Yu, Y., et al. “1017P AdvanTIG-105: Phase Ib Dose-Expansion Study of Ociperlimab (OCI) + Tislelizumab (TIS) with Chemotherapy (Chemo) in Patients (Pts) with Metastatic Squamous (Sq) and Non-Squamous (Non-Sq) Non-Small Cell Lung Cancer (NSCLC).” Annals of Oncology, vol. 33, Sept. 2022, p. S1019. EBSCOhost, https://doi.org/10.1016/j.annonc.2022.07.1143.
APA
Yu, Y., Huang, D., Gao, B., Zhao, J., Hu, Y., Zhuang, W., Kao, S., Xu, W., Yao, Y., Yang, T.-Y., Lee, Y., Kim, J.-S., Shiah, H.-S., Wang, R., Zheng, H., Tan, W., Gao, R., Kim, H. R., & Lu, S. (2022). 1017P AdvanTIG-105: Phase Ib dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS) with chemotherapy (chemo) in patients (pts) with metastatic squamous (sq) and non-squamous (non-sq) non-small cell lung cancer (NSCLC). Annals of Oncology, 33, S1019. https://doi.org/10.1016/j.annonc.2022.07.1143
Chicago
Yu, Y., D. Huang, B. Gao, J. Zhao, Y. Hu, W. Zhuang, S. Kao, et al. 2022. “1017P AdvanTIG-105: Phase Ib Dose-Expansion Study of Ociperlimab (OCI) + Tislelizumab (TIS) with Chemotherapy (Chemo) in Patients (Pts) with Metastatic Squamous (Sq) and Non-Squamous (Non-Sq) Non-Small Cell Lung Cancer (NSCLC).” Annals of Oncology 33 (September): S1019. doi:10.1016/j.annonc.2022.07.1143.